Virological and immunological outcome of treatment interruption in HIV-1-infected subjects vaccinated with MVA-B.
The most relevant endpoint in therapeutic HIV vaccination is the assessment of time to viral rebound or duration of sustained control of low-level viremia upon cART treatment cessation. Structured treatment interruptions (STI) are however not without risk to the patient and reliable predictors of vi...
Main Authors: | Miriam Rosás-Umbert, Beatriz Mothe, Marc Noguera-Julian, Rocío Bellido, Maria C Puertas, Jorge Carrillo, C Rodriguez, Núria Perez-Alvarez, Patricia Cobarsí, Carmen E Gomez, Mariano Esteban, Jose Luis Jímenez, Felipe García, Julià Blanco, Javier Martinez-Picado, Roger Paredes, Christian Brander |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2017-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5617163?pdf=render |
Similar Items
-
Impact of ChAdOx1 or DNA Prime Vaccination on Magnitude, Breadth, and Focus of MVA-Boosted Immunogen-Specific T Cell Responses
by: Alex Olvera, et al.
Published: (2024-03-01) -
The immunological and virological consequences of planned treatment interruptions in children with HIV infection
by: Klein, N, et al.
Published: (2013) -
Highly active antiretroviral therapy interruption: predictors and virological and immunologic consequences.
by: Touloumi, G, et al.
Published: (2006) -
The immunological and virological consequences of planned treatment interruptions in children with HIV infection.
by: Nigel Klein, et al.
Published: (2013-01-01) -
Virologic and immunologic correlates of viral control after ART-interruption in SIV-infected rhesus macaques
by: M. Paiardini, et al.
Published: (2015-12-01)